Global Antihormonal Cancer Therapies Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Antihormonal Cancer Therapies Market Overview

• 1.1 Product Overview and Scope of Antihormonal Cancer Therapies
• 1.2 Classification of Antihormonal Cancer Therapies by Types
  • 1.2.1 Global Antihormonal Cancer Therapies Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Antihormonal Cancer Therapies Revenue Market Share by Types in 2018
  • 1.2.3 Radiations
  • 1.2.4 Drugs
  • 1.2.5 Surgeries
  • 1.2.6 Others
• 1.3 Global Antihormonal Cancer Therapies Market by Application
  • 1.3.1 Global Antihormonal Cancer Therapies Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Breast Cancer
  • 1.3.3 Prostate Cancer
  • 1.3.4 Other
• 1.4 Global Antihormonal Cancer Therapies Market by Regions
  • 1.4.1 Global Antihormonal Cancer Therapies Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Antihormonal Cancer Therapies Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Antihormonal Cancer Therapies Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Antihormonal Cancer Therapies Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Antihormonal Cancer Therapies Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Antihormonal Cancer Therapies Status and Prospect (2014-2024)
• 1.5 Global Market Size of Antihormonal Cancer Therapies (2014-2024)

2 Company Profiles

• 2.1 AstraZeneca
  • 2.1.1 Business Overview
  • 2.1.2 Antihormonal Cancer Therapies Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 AstraZeneca Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Samyang Biopharmaceuticals
  • 2.2.1 Business Overview
  • 2.2.2 Antihormonal Cancer Therapies Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Samyang Biopharmaceuticals Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Sanofi
  • 2.3.1 Business Overview
  • 2.3.2 Antihormonal Cancer Therapies Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Sanofi Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Novartis
  • 2.4.1 Business Overview
  • 2.4.2 Antihormonal Cancer Therapies Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Novartis Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Amgen
  • 2.5.1 Business Overview
  • 2.5.2 Antihormonal Cancer Therapies Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Amgen Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Pfizer
  • 2.6.1 Business Overview
  • 2.6.2 Antihormonal Cancer Therapies Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Pfizer Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Bluebird Bio
  • 2.7.1 Business Overview
  • 2.7.2 Antihormonal Cancer Therapies Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Bluebird Bio Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Roche
  • 2.8.1 Business Overview
  • 2.8.2 Antihormonal Cancer Therapies Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Roche Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Takeda
  • 2.9.1 Business Overview
  • 2.9.2 Antihormonal Cancer Therapies Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Takeda Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Tolmar
  • 2.10.1 Business Overview
  • 2.10.2 Antihormonal Cancer Therapies Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Tolmar Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Bristol-Myers Squibb
  • 2.11.1 Business Overview
  • 2.11.2 Antihormonal Cancer Therapies Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Bristol-Myers Squibb Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Illumina
  • 2.12.1 Business Overview
  • 2.12.2 Antihormonal Cancer Therapies Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Illumina Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Exelixis
  • 2.13.1 Business Overview
  • 2.13.2 Antihormonal Cancer Therapies Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Exelixis Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Guardant Health
  • 2.14.1 Business Overview
  • 2.14.2 Antihormonal Cancer Therapies Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Guardant Health Antihormonal Cancer Therapies Revenue, Gross Margin and Market Share (2017-2018)

3 Global Antihormonal Cancer Therapies Market Competition, by Players

• 3.1 Global Antihormonal Cancer Therapies Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Antihormonal Cancer Therapies Players Market Share
  • 3.2.2 Top 10 Antihormonal Cancer Therapies Players Market Share
• 3.3 Market Competition Trend

4 Global Antihormonal Cancer Therapies Market Size by Regions

• 4.1 Global Antihormonal Cancer Therapies Revenue and Market Share by Regions
• 4.2 North America Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 4.3 Europe Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 4.5 South America Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)

5 North America Antihormonal Cancer Therapies Revenue by Countries

• 5.1 North America Antihormonal Cancer Therapies Revenue by Countries (2014-2019)
• 5.2 USA Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 5.3 Canada Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)

6 Europe Antihormonal Cancer Therapies Revenue by Countries

• 6.1 Europe Antihormonal Cancer Therapies Revenue by Countries (2014-2019)
• 6.2 Germany Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 6.3 UK Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 6.4 France Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 6.5 Russia Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 6.6 Italy Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Antihormonal Cancer Therapies Revenue by Countries

• 7.1 Asia-Pacific Antihormonal Cancer Therapies Revenue by Countries (2014-2019)
• 7.2 China Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 7.3 Japan Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 7.4 Korea Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 7.5 India Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)

8 South America Antihormonal Cancer Therapies Revenue by Countries

• 8.1 South America Antihormonal Cancer Therapies Revenue by Countries (2014-2019)
• 8.2 Brazil Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Antihormonal Cancer Therapies by Countries

• 9.1 Middle East and Africa Antihormonal Cancer Therapies Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 9.3 UAE Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Antihormonal Cancer Therapies Revenue and Growth Rate (2014-2019)

10 Global Antihormonal Cancer Therapies Market Segment by Type

• 10.1 Global Antihormonal Cancer Therapies Revenue and Market Share by Type (2014-2019)
• 10.2 Global Antihormonal Cancer Therapies Market Forecast by Type (2019-2024)
• 10.3 Radiations Revenue Growth Rate (2014-2024)
• 10.4 Drugs Revenue Growth Rate (2014-2024)
• 10.5 Surgeries Revenue Growth Rate (2014-2024)
• 10.6 Others Revenue Growth Rate (2014-2024)

11 Global Antihormonal Cancer Therapies Market Segment by Application

• 11.1 Global Antihormonal Cancer Therapies Revenue Market Share by Application (2014-2019)
• 11.2 Antihormonal Cancer Therapies Market Forecast by Application (2019-2024)
• 11.3 Breast Cancer Revenue Growth (2014-2019)
• 11.4 Prostate Cancer Revenue Growth (2014-2019)
• 11.5 Other Revenue Growth (2014-2019)

12 Global Antihormonal Cancer Therapies Market Size Forecast (2019-2024)

• 12.1 Global Antihormonal Cancer Therapies Market Size Forecast (2019-2024)
• 12.2 Global Antihormonal Cancer Therapies Market Forecast by Regions (2019-2024)
• 12.3 North America Antihormonal Cancer Therapies Revenue Market Forecast (2019-2024)
• 12.4 Europe Antihormonal Cancer Therapies Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Antihormonal Cancer Therapies Revenue Market Forecast (2019-2024)
• 12.6 South America Antihormonal Cancer Therapies Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Antihormonal Cancer Therapies Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology